The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression
Abstract
Genetic factors play a significant but complex role in antidepressant (AD) response and tolerability. During recent years, there is growing enthusiasm in the promise of pharmacogenetic/pharmacogenomic (PGx) tools for optimizing and personalizing treatment outcomes for patients with major depressive disorder (MDD). The influence of pharmacokinetic and pharmacodynamic genes on response and tolerability has been investigated, including those encoding the cytochrome P450 superfamily, P-glycoprotein, monoaminergic transporters and receptors, intracellular signal transduction pathways, and the stress hormone system. Genome-wide association studies are also identifying new genetic variants associated with AD response phenotypes, which, combined with methods such as polygenic risk scores (PRS), is opening up new avenues for novel personalized treatment approaches for MDD. This chapter describes the basic concepts in PGx of AD response, reviews the major pharmacokinetic and pharmacodynamic genes involved in AD outcome, discusses PRS as a promising approach for predicting AD efficacy and tolerability, and addresses key challenges to the development and application of PGx tests.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies suggest that blood levels of sertraline, a common first-line antidepressant, can successfully be predicted through analysis of genes involved in sertraline metabolism and thus, giving an indication of drug effectiveness204-206.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [204]
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Hicks, J., Sangkuhl, K., Swen, J., Ellingrod, V., Müller, D., Shimoda, K., Bishop, Jr., Kharasch, E., Skaar, T., Gaedigk, A., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.597 · Cited by 685
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy
Holsboer, F. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00352-9 · Cited by 575
Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529
Treatment selection in depression.
Cohen, Z. D., & DeRubeis, R. J. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084746 · Cited by 435
Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31276-0 · Cited by 427
Uhr, M., Tontsch, A., Namendorf, C., Ripke, S., Lucae, S., Ising, M., Dose, T., Ebinger, M., Rosenhagen, M., Kohli, M., et al. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.017 · Cited by 382
Porcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331
Polymorphisms of the Glucocorticoid Receptor Gene and Major Depression
van Rossum, E. F. C., Binder, E. B., Majer, M., Koper, J. W., Ising, M., Modell, S., Salyakina, D., Lamberts, S. W. J., & Holsboer, F. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.007 · Cited by 324
Research works printed but not linked: 1
- Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K et al (2017) Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 102(1):37–44 · DOI · Paper page
Cited by
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01520-y · Cited by 408
Carta, A., Zompo, M. D., Meloni, A., Molà, F., Paribello, P., Pinna, F., Pinna, M., Pisanu, C., Manchia, M., Squassina, A., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01182-2 · Cited by 24
“Indeed, genetic variants have been suggested to explain part of the large interindividual variability observed in response to antidepressants and in the onset of adverse effects, with most robust evidence available for genes involved in the metabolism of these drugs such as genes encoding cytochrome P450 (CYP) enzymes…”
BackgroundBeer, C., Rae, F., Semmler, A., & Voisey, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147992 · Cited by 16
“…this a possibility , and the science of combining pharmacology with genomics or ‘phar-macogenomics (PGx)’ potentially offers an avenue for more targeted medication in depression by minimising the trial-and-error approach to prescribing antidepressants [36,37]. approach in mind will be essential.”
BackgroundRoelofsen, A., Kreeftenberg, L. L., van El, C. G., Henneman, L., Rigter, T., Sie, D., Bet, P. M., & Cornel, M. C. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2504862 · Cited by 7
“To enable HCPs to interpret PGx results, the need for standardized and streamlined education was stressed [45].”
Islam, F., Lisoway, A. J., Oh, E. S., Fiori, L. M., Magarbeh, L., Elsheikh, S. S. M., Kim, H. K., Kloiber, S. M., Kennedy, J. L., Frey, B. N., et al. (2024) · Pharmacopsychiatry · doi:10.1055/a-2313-9979 · Cited by 6
Self-citation
Metadata
- Authors
- Islam, F., Gorbovskaya, I., & Müller, D. J.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer Singapore
- Published
- 2021
- Volume
- 1305
- Pages
- 231-255
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W3142542217
- Cited by
- 6
- References
- 117
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 3
- FWCI
- 5.04
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- pharmacogenetics, pharmacogenomics, major depressive disorder, antidepressant response, antidepressant tolerability, personalized treatment, polygenic risk score, cytochrome P450, P-glycoprotein, monoaminergic receptors, intracellular signaling, genome-wide association study, pharmacokinetic genes
- MeSH terms
- Antidepressive Agents, Depression, Major Depressive Disorder, Humans, Pharmacogenetics, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression. https://app.cochat.ai/papers/10.1007/978-981-33-6044-0_13
- The paper
- Islam, F., Gorbovskaya, I., & Müller, D. J. (2021). Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-981-33-6044-0_13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.